Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Leqembi is a medication designed to slow the progression of Alzheimer's disease in its early stages. Approved by the FDA, Leqembi offers hope to patients diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. This medication targets and helps to clear out amyloid beta plaques, a hallmark of Alzheimer's, which are believed to play a crucial role in the degeneration of neurons in the brain.
Leqembi is specifically tailored for individuals who have confirmed accumulation of amyloid beta in their brains, which can be determined through imaging tests. The administration of Leqembi can potentially improve cognitive function, delay cognitive decline, and maintain independence for a longer period in the disease's progression. Before you buy Leqembi , it is crucial that you talk to your healthcare provider about potential side effects and Leqembi cost.
| Fact Table | |
|---|---|
| Formula | C6476H9996N1724O2010S44 (monoclonal antibody) |
| License | FDA approved (Accelerated Approval) |
| Bioavailability | Not available (IV administration) |
| Legal status | Prescription Drugs |
| Chemical Name | Lecanemab |
| Elimination half-life | Approximately 6-10 days |
| Dosage (Strength) | 200 mg or 500 mg vials, administered intravenously |
| Pregnancy | Not recommended (Category N/A) |
| Brands | Leqembi |
| Protein binding | High protein binding due to monoclonal antibody structure |
| PubChem CID | Not available |
| MedlinePlus | Not listed |
| ChEBI | Not available |
| ATC code | Not available |
| DrugBank | DB15175 (Lecanemab) |
| KEGG | D11964 (Lecanemab) |
| Routes of administration | Intravenous |
Leqembi dosage is administered as an intravenous infusion. It is crucial to follow the specific instructions provided by healthcare providers who will administer the medication in a clinical setting. Leqembi is administered as a bi-weekly infusion for the first three months. After the initial phase, the treatment frequency is usually adjusted based on patient response and tolerability.
Active Ingredient: Lecanemab
Leqembi is not suitable for all patients with Alzheimer's disease; it is only indicated for those with mild cognitive impairment or mild dementia stages of the disease with confirmed amyloid pathology.
Before starting treatment, patients must undergo brain imaging to confirm the presence of amyloid plaques.
Regular monitoring of brain imaging is recommended to assess changes in amyloid levels and to monitor for potential side effects like amyloid-related imaging abnormalities (ARIA), which can include brain swelling or microhemorrhages.
Routine blood tests may be required to monitor for other potential side effects.
Leqembi can interact with other medications, which may alter its effectiveness or increase the risk of side effects. It is important to discuss all medications, including over-the-counter drugs and supplements, with the healthcare provider. Possible Interactions include immunosuppressants, anti-inflammatory drugs and other medications for Alzheimer's disease.
Common side effects:
What is Leqembi used for?
Leqembi (lecanemab-irmb) is used to treat Alzheimer’s disease in adults who have mild cognitive impairment or mild dementia.
How does Leqembi work?
Leqembi works by reducing the amount of beta-amyloid plaques in the brain, which are thought to play a key role in Alzheimer’s disease.
How is Leqembi administered?
Leqembi is given as an intravenous (IV) infusion over approximately one hour, once every two weeks.
How long do you take Leqembi?
Leqembi is typically taken once every two weeks for as long as it is effective and side effects are manageable.
Is Leqembi effective?
Leqembi has shown some effectiveness in slowing cognitive decline in people with early Alzheimer’s disease, but it is not a cure.
What are the side effects of Leqembi?
Common side effects of Leqembi include headache, cough, diarrhea, and infusion-related reactions. Serious side effects can include brain swelling or small spots of bleeding in the brain.
Who should not take Lecanemab?
Lecanemab (Leqembi) is not recommended for people with full cognitive function or those in the later stages of Alzheimer’s disease.
How long does it take for Leqembi to work?
Leqembi starts to work after the first dose, but because of how the drug works, patients likely won’t feel the drug working in their body.
